FLNA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Filana Therapeutics, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.01 USD
13.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is - below the Trend Line and sits at 9.4% of its 52-week range. The latest completed week returned 13.4%, after a -17.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 25 out of 100
Latest Close 1.01 USD 31 Jul 2026
1W Return 13.4% latest completed week
4W Return -17.9% short-term follow-through
12W Return - quarterly tape
Trend Breadth 0.0% 0 of 12 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
  • Next-week expectancy is negative at 9.96% based on similar historical setup states.
What to watch next
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 13.4% Latest completed week; four-week move -17.9%. Indicator stack 0/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 9.96% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 53/100 conviction; expected move 26.4%. News sentiment 49/100 21 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is - below the Trend Line and sits at 9.4% of its 52-week range. The latest completed week returned 13.4%, after a -17.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Mar 20 Mar 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0012-week average 0.00

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -17.9% over four weeks, - over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W13.4%
4W-17.9%
12W-
26W-
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 55% Model confidence 52%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength61/100Blend of value, momentum, and quality. Underlying universe rank 40; rank 1 is best.
Value55/100Relative valuation strength. Underlying universe rank 46; rank 1 is best.
Quality53/100Profitability and accounting quality. Underlying universe rank 48; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-67.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

FLNA shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 26.4%, and Sharemaestro trend signal inactive.

Conviction53/100
Expected move26.4%
Put/call volume0.00
Pressure100
Speculation4
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 21 relevant articles.

1 positive · 18 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move26.4%Nearest-chain priced movement where available.
52-week drawdown-59.4%Distance below the 52-week high.
13-week volatility8.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher2 of 119 weeks finished lower.
Best week+13.4%Week of 31 Jul.
Worst week-16.0%Week of 24 Jul.
Latest week+13.4%Week of 31 Jul.

Shape of recent returns

Strong gains1
Modest gains1
Flat weeks0
Modest losses2
Sharp losses7
Recent vol8.2%13-week weekly-return volatility.
Base vol8.2%52-week weekly-return volatility.
Up/down split2/9Count of positive and negative weeks in the 52-week window.
Average skew7.9% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis18/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.00; No reversal markers Next-Week ExpectancyNegative 9.96%

Next-week expectancy is negative with a 9.96% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors55/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 48 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

FLNA shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 26.4%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 26.4% Sentiment49/100

Weighted news tone is neutral across 21 relevant articles.

Filana Therapeutics Q2 EPS beats estimate, loss narrows 81% Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.01 USD13.4%-1.31 USD0.00-1.3MOff
24 Jul 20260.89 USD-16.0%-1.33 USD0.00-1.9MOff
17 Jul 20261.06 USD-10.2%-1.38 USD0.00-1.6MOff
10 Jul 20261.18 USD-4.1%-1.41 USD0.00-2.2MOff
3 Jul 20261.23 USD2.5%-1.44 USD0.00-1.5MOff
26 Jun 20261.20 USD-1.6%-1.47 USD0.00-1.6MOff
19 Jun 20261.22 USD-2.4%-1.52 USD0.00-1.7MOff
12 Jun 20261.25 USD-5.3%-1.58 USD0.00-1.4MOff
5 Jun 20261.32 USD-14.3%-1.66 USD0.00-1.8MOff
29 May 20261.54 USD-14.0%-1.77 USD--911.9KOff
20 Mar 20261.79 USD-10.1%-1.89 USD--2.3MOff
13 Mar 20261.99 USD--1.99 USD--4.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.